CRH plc CRH ← Back to all reports

CRH plc

CRH · Materials
S ★★★★★ Strong Buy
Jul 11, 2026 · Score 95 · Type A — Value-style analysis Used for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety. Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology → $104.71
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses. $100.00 ($95.00–$105.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology → $143.00
Expected Return
  • Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
  • A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Methodology →
+36.6%

Type A - CRH plc (CRH) 20260711 Stock Analysis

📅 CRH Key Upcoming Events

🏢 Step 1: CRH Company Overview & Business Model

Q1-A1. What is CRH?

Q1-A2. How Does CRH Make Money?

Q1-A3. CRH’s Revenue Segments & Core Income Sources

Q1-A4. Who Are CRH’s Competitors?

Q1-A5. CRH Key Events: Past 12 Months

Q1-A6. Step 1 Key Takeaways

🏰 Step 2: CRH’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does CRH Have a Durable Economic Moat?

Q2-A2. Is CRH’s Growth Sustainable?

Q2-A3. How Does CRH Allocate Capital & Return Cash?

Q2-A4. Step 2 Key Takeaways

💰 Step 3: Is CRH Profitable? Financial Health Analysis

Q3-A2. How Profitable Is CRH? (Margins & ROIC)

Q3-A3. What Drives CRH’s Returns? (ROIC Breakdown)

Q3-A4. Are CRH’s Earnings High Quality?

Q3-A5. Is CRH’s Balance Sheet Healthy? (Debt & Leverage)

Q3-A6. Step 3 Key Takeaways

🔎 Step 4: CRH Forensic Accounting & Dilution Review

Q4-A1. Does CRH Have Accounting Red Flags?

Q4-A2. Is CRH Overspending? (Capex & Capital Cycle)

Q4-A3. How Sound Is CRH’s Cash Flow?

Q4-A4. Is CRH Diluting Shareholders?

Q4-A5. Data Integrity Check

Q4-A6. Step 4 Key Takeaways

👔 Step 5: CRH Management & Shareholder Alignment

Q5-A1. Can You Trust CRH’s Management? (Guidance Track Record)

Q5-A2. What Are CRH Insiders Doing?

Q5-A3. Is CRH’s Management Aligned With Shareholders?

Q5-A4. Step 5 Key Takeaways

⛵ Step 6: CRH Market Flow & Sentiment

Q6-A1. Analyst Consensus vs CRH Guidance

Q6-A2. What Is CRH’s Short Interest?

Q6-A3. Step 6 Key Takeaways

🚀 Step 7: CRH Catalysts & Price Triggers

Q7-A1. What Could Move CRH Stock? (Top 3 Catalysts)

Q7-A2. CRH’s Earnings Revision Trend

Q7-A3. Step 7 Key Takeaways

⚖️ Step 8: Is CRH Fairly Valued? Valuation Analysis

Q8-A1. CRH’s Key Valuation Multiples (P/E, EV/EBITDA)

Q8-A2. CRH vs Peers: Valuation Comparison

Q8-A3. Is CRH Cheap or Expensive vs Its History?

Q8-A4. What Growth Is Priced Into CRH? (Reverse DCF)

Q8-A5. Valuation Cross-Check

Q8-A6. CRH’s Asset & Stake Valuation

Q8-A7. Final Valuation Adjustment

Q8-A8. Valuation Adjustment Score Calculation

💀 Step 9: What Are the Risks of CRH? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to CRH?

Q9-A2. How Sensitive Is CRH to the Economy?

Q9-A3. CRH Pre-Mortem: What Could Go Wrong?

Q9-A4. Risk Adjustment Score Calculation

🎯 Step 10: CRH Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

Q10-A2. Should You Buy CRH? (Recommendation)

Q10-A3. Investment Thesis in One Line

Q10-A4. CRH’s Price Trend & Key Drivers

Q10-A5. Action Plan

🕵️‍♂️ Deep Dive Analysis

Q1: Is CRH’s Heavy Debt Load From the Monumental $8.5 Billion Arcosa Acquisition Its Biggest Weakness?

Q2: Can CRH’s 17.5x Forward P/E Be Fundamentally Justified by the North American Infrastructure Supercycle?

Q3: Will CRH’s Americas Building Solutions Segment Survive a Prolonged High-Interest Rate Housing Recession?

Q4: Does the $2.1 Billion Eco Material Technologies Acquisition Provide a Genuine Sustainability Moat?

Q5: Is CRH’s Unprecedented 12-Year Streak of EBITDA Margin Expansion Nearing an Absolute Ceiling?

Q6: Can the New $300 Million Quarterly Buyback Tranche Keep Pace With the Imminent Arcosa Debt Servicing?

Q7: Will Heightened Regulatory Antitrust Scrutiny Derail the Historic Arcosa Merger?

Q8: Does CRH’s Relisting to the NYSE Completely Eliminate the Historical “European Conglomerate” Discount?

Q9: How Vulnerable is CRH’s International Solutions Segment to Ongoing European Macro Weakness?

Q10: Is the “CRH Winning Way” Merely Corporate Jargon, or a Quantifiable Strategic Advantage?

CRH plc (CRH)